Key result
Pre-symptomatic SMA treatment is linked to improved motor outcomes, with ~75% walking independently.
Why the study?
Disease-modifying therapies for spinal muscular atrophy provide significant benefits, making newborn screening essential for timely diagnosis and treatment initiation.
Does newborn screening and pre-symptomatic treatment improve motor function development in infants with spinal muscular atrophy?
Does newborn screening and pre-symptomatic treatment improve motor function development in infants with spinal muscular atrophy?
Pre-symptomatic treatment following newborn screening for spinal muscular atrophy markedly improves motor function development, supporting the need for large-scale screening programs.
Answers are grounded in this paper and cite their sources.
Supports newborn SMA screening to enable pre-symptomatic therapy; extends trial evidence to real-world cohorts.
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder causing progressive muscle weakness. Severe SMA forms are typically observed up to six months postnatally. Disease-modifying therapies provide significant benefits, making newborn screening (NBS) essential for timely diagnosis and treatment initiation. The NBS programme evaluated infants born between April 2023 and October 2024 in the Campania region, Italy. DNA was amplified to detect homozygous deletion of the SMN1 gene by RT-PCR and SMN2 copy number using multiplex ligation-dependent probe amplification. Following treatment, motor functions were assessed using CHOP-INTEND and Bayley III scales. Among 62,801 infants screened for SMA, thirteen (11 females, 2 males) tested positive. The distribution of SMN2 copy numbers was as follows: eight patients had two copies, one patient had three, and four patients had four copies. One year after treatment, motor outcome data were available for four of the eight patients with two SMN2 copies. Among these patients, one achieved the milestones of walking without support, and three were standing with support. At 24 months, three of these patients were walking independently. Pre-symptomatic treatment markedly improves motor function development. This underscores the urgent need for large-scale newborn screening to prevent diagnostic delays and ensure timely, effective therapy. Validated care protocols must be established to facilitate early diagnosis and intervention.
No takes yet. Share an insight, caveat, or question.
Bitetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: